483 related articles for article (PubMed ID: 27164828)
1. [Systemic treatment of inoperable metastasized malignant melanoma].
Gutzmer R; Rauschenberg R; Meier F
Hautarzt; 2016 Jul; 67(7):529-35. PubMed ID: 27164828
[TBL] [Abstract][Full Text] [Related]
2. Survival of patients with advanced metastatic melanoma: the impact of novel therapies-update 2017.
Ugurel S; Röhmel J; Ascierto PA; Flaherty KT; Grob JJ; Hauschild A; Larkin J; Long GV; Lorigan P; McArthur GA; Ribas A; Robert C; Schadendorf D; Garbe C
Eur J Cancer; 2017 Sep; 83():247-257. PubMed ID: 28756137
[TBL] [Abstract][Full Text] [Related]
3. Combining BRAF/MEK Inhibitors with Immunotherapy in the Treatment of Metastatic Melanoma.
Ziogas DC; Konstantinou F; Bouros S; Theochari M; Gogas H
Am J Clin Dermatol; 2021 May; 22(3):301-314. PubMed ID: 33765322
[TBL] [Abstract][Full Text] [Related]
4. The Systemic Management of Advanced Melanoma in 2016.
Heppt MV; Dietrich C; Graf SA; Ruzicka T; Tietze JK; Berking C
Oncol Res Treat; 2016; 39(10):635-642. PubMed ID: 27710977
[TBL] [Abstract][Full Text] [Related]
5. Recent advances in molecular targeted therapy for unresectable and metastatic BRAF-mutated melanoma.
Kiniwa Y; Okuyama R
Jpn J Clin Oncol; 2021 Mar; 51(3):315-320. PubMed ID: 33338202
[TBL] [Abstract][Full Text] [Related]
6. Systemic treatment for BRAF-mutant melanoma: where do we go next?
Menzies AM; Long GV
Lancet Oncol; 2014 Aug; 15(9):e371-81. PubMed ID: 25079100
[TBL] [Abstract][Full Text] [Related]
7. Outcomes in Melanoma Patients Treated with BRAF/MEK-Directed Therapy or Immune Checkpoint Inhibition Stratified by Clinical Trial versus Standard of Care.
Goldman C; Tchack J; Robinson EM; Han SW; Moran U; Polsky D; Berman RS; Shapiro RL; Ott PA; Osman I; Zhong H; Pavlick AC; Wilson MA
Oncology; 2017; 93(3):164-176. PubMed ID: 28601879
[TBL] [Abstract][Full Text] [Related]
8. Immunomodulatory Effects of BRAF, MEK, and CDK4/6 Inhibitors: Implications for Combining Targeted Therapy and Immune Checkpoint Blockade for the Treatment of Melanoma.
Lelliott EJ; McArthur GA; Oliaro J; Sheppard KE
Front Immunol; 2021; 12():661737. PubMed ID: 34025662
[TBL] [Abstract][Full Text] [Related]
9. Developments in targeted therapy in melanoma.
Amann VC; Ramelyte E; Thurneysen S; Pitocco R; Bentele-Jaberg N; Goldinger SM; Dummer R; Mangana J
Eur J Surg Oncol; 2017 Mar; 43(3):581-593. PubMed ID: 27923592
[TBL] [Abstract][Full Text] [Related]
10. Recent advances in malignant melanoma.
Atkinson V
Intern Med J; 2017 Oct; 47(10):1114-1121. PubMed ID: 28994264
[TBL] [Abstract][Full Text] [Related]
11. Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF(V600E) melanoma.
Hu-Lieskovan S; Mok S; Homet Moreno B; Tsoi J; Robert L; Goedert L; Pinheiro EM; Koya RC; Graeber TG; Comin-Anduix B; Ribas A
Sci Transl Med; 2015 Mar; 7(279):279ra41. PubMed ID: 25787767
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and Safety of Nivolumab in Patients With BRAF V600 Mutant and BRAF Wild-Type Advanced Melanoma: A Pooled Analysis of 4 Clinical Trials.
Larkin J; Lao CD; Urba WJ; McDermott DF; Horak C; Jiang J; Wolchok JD
JAMA Oncol; 2015 Jul; 1(4):433-40. PubMed ID: 26181250
[TBL] [Abstract][Full Text] [Related]
13. Targeted agents and immunotherapies: optimizing outcomes in melanoma.
Luke JJ; Flaherty KT; Ribas A; Long GV
Nat Rev Clin Oncol; 2017 Aug; 14(8):463-482. PubMed ID: 28374786
[TBL] [Abstract][Full Text] [Related]
14. [Response of BRAF(L597Q)-mutant melanoma to trametinib : Targeted melanoma therapy beyond BRAF(V600) mutations].
Haase O; Angün O; Grätz V; Lüttmann N; Neumann A; Zillikens D; Terheyden P
Hautarzt; 2016 Aug; 67(8):648-52. PubMed ID: 27146499
[TBL] [Abstract][Full Text] [Related]
15. Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety study.
Larkin J; Del Vecchio M; Ascierto PA; Krajsova I; Schachter J; Neyns B; Espinosa E; Garbe C; Sileni VC; Gogas H; Miller WH; Mandalà M; Hospers GA; Arance A; Queirolo P; Hauschild A; Brown MP; Mitchell L; Veronese L; Blank CU
Lancet Oncol; 2014 Apr; 15(4):436-44. PubMed ID: 24582505
[TBL] [Abstract][Full Text] [Related]
16. [Targeted molecular therapies (except immunotherapy)].
Roux J; Pages C; Lebbé C
Bull Cancer; 2014 Dec; 101 Suppl 2():S25-36. PubMed ID: 25776764
[TBL] [Abstract][Full Text] [Related]
17. Patterns of treatment and BRAF testing with immune checkpoint inhibitors and targeted therapy in patients with metastatic melanoma presumed to be BRAF positive.
Ghate S; Ionescu-Ittu R; Burne R; Ndife B; Laliberté F; Nakasato A; Duh MS
Melanoma Res; 2019 Jun; 29(3):301-310. PubMed ID: 30247203
[TBL] [Abstract][Full Text] [Related]
18. Molecular genetic and immunotherapeutic targets in metastatic melanoma.
Melis C; Rogiers A; Bechter O; van den Oord JJ
Virchows Arch; 2017 Aug; 471(2):281-293. PubMed ID: 28357489
[TBL] [Abstract][Full Text] [Related]
19. Successful (neo)adjuvant BRAF-targeted therapy in a patient with locally advanced BRAF V600E mutant melanoma.
Seremet T; Lienard D; Suppa M; Trepant AL; Rorive S; Woff E; Cuylits N; Jansen Y; Schreuer M; Del Marmol V; Neyns B
Melanoma Res; 2015 Apr; 25(2):180-3. PubMed ID: 25643238
[TBL] [Abstract][Full Text] [Related]
20. Targeting RAS/RAF/MEK/ERK signaling in metastatic melanoma.
Wang AX; Qi XY
IUBMB Life; 2013 Sep; 65(9):748-58. PubMed ID: 23893853
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
